Novel drug candidate found to be generally safe and well-tolerated in inflammatory indications More: Galapagos reports early clinical results for SIK inhibitor Source: News
read moreAt the same time, Affinivax and Astellas revealed positive results from the Phase II trial of ASP3772 More: Affinivax, Astellas’ pneumococcal vaccine wins breakthrough therapy status Source: News
read moreInvestment raised by its spinouts more than doubled in the last year, the charity has reported More: Cancer Research UK reports ‘most successful financial year’ for its spinouts Source: News
read moreThe positive opinion has been issued via the MHRA’s early access the medicine (EAMS) scheme More: Merck’s MET inhibitor tepotinib gains positive opinion from MHRA Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals